Abstract
Purpose :
Intravitreal dexamethasone implants (Ozurdex) are not currently indicated for cystoid macular edema (CME), although they are currently being used as therapy for this condition. Additionally, little data exists on the affects of an intravitreal dexamethasone implant as a treatment for CME. We conducted a retrospective chart review to determine changes in visual function and macular thickness following treatment with an intravitreal dexamethasone implant in patients with CME.
Methods :
This chart review included 31 eyes in 28 patients who received at least one intravitreal dexamethasone injection for treatment of CME. Visual acuity (VA) and optical coherence tomography central subfield thickness (CST) were compared before and after the first intravitreal dexamethasone implant. P value was calculated from a 2-tailed paired T-test with a statistical significance value of P<0.05.
Results :
In 27 out of 31 eyes, after 1 intravitreal dexamethasone implant, there was significant improvement in peak ETDRS VA (mean +15.5 letters, p=0.00001). The peak ETDRS VA change ranged from -12 to +65 letters. There was a significant decrease in CST in 30 out of 31 eyes after 1 intravitreal dexamethasone implant (mean -168.6 μm, p=0.0004). The CST ranged from a peak decrease of 1204 μm to an increase of 22 μm. Intraocular pressure increased in 27 out of 31 eyes. 8 eyes reached an intraocular pressure of ≥25 mmHg with 4 of these reaching an intraocular pressure of ≥30 mmHg.
Conclusions :
Treatment with an intravitreal dexamethasone implant may significantly benefit VA and CST in patients with CME.
This is a 2021 ARVO Annual Meeting abstract.